SCHEMBL2125262

SCHEMBL2125262

Cc1ccc(-c2nc3c(C#N)c[nH]n3c2Nc2ccccc2Cl)s1

nearest known ligand 0.44

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
▸ GAA P10253 4/20 0.44
▸ MAPT P10636 3/20 0.44
▸ SMN1; SMN2 Q16637 1/20 0.44
▸ TP53 P04637 4/20 0.43
▸ KDM5A P29375 13/20 0.43
▸ POLB P06746 1/20 0.40
▸ KDM6B O15054 1/20 0.40
▸ KDM5C P41229 1/20 0.40
▸ KDM5D Q9BY66 1/20 0.40
▸ KDM4C Q9H3R0 1/20 0.40
▸ KDM5B Q9UGL1 1/20 0.40
▸ PHF8 Q9UPP1 1/20 0.40
▸ KDM4E B2RXH2 1/20 0.39
▸ CYP2D6 P10635 1/20 0.39
▸ CYP2C9 P11712 1/20 0.39
▸ FPR1 P21462 1/20 0.39
▸ CYP2C19 P33261 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2124006 0.83 KDM5A (0.53) MAPTTP53KDM5APOLBKDM6B
SCHEMBL2873336 0.83 KDM5A (0.55) MAPTTP53KDM5AKDM6BKDM5C
SCHEMBL2124358 0.82 MAPT (0.42) MAPTTP53KDM5AKDM6BKDM5C
SCHEMBL2126197 0.81 KDM5A (0.53) MAPTTP53KDM5APOLBKDM6B
SCHEMBL2124952 0.80 KDM5A (0.52) MAPTTP53KDM5APOLBKDM6B
SCHEMBL2123600 0.79 KDM5A (0.41) GAAMAPTTP53KDM5AKDM6B
SCHEMBL2123478 0.79 MAPT (0.43) MAPTTP53KDM5AKDM6BKDM5C
SCHEMBL2875656 0.79 MAPT (0.50) MAPTTP53KDM5APOLBKDM6B
SCHEMBL2126298 0.79 MAPT (0.46) MAPTTP53KDM5APOLBKDM6B
SCHEMBL2125131 0.79 MAPT (0.46) MAPTTP53KDM5APOLBKDM6B

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2443123-B1 SMALL MOLECULE INHIBITORS OF SPLEEN TYROSINE KINASE (SYK) RIGEL PHARMACEUTICALS INC (US) 2017-04-05 — — EP disclosed
US-8377945-B2 Small molecule inhibitors of spleen tyrosine kinase (SYK) RIGEL PHARMACEUTICALS INC. (US) 2013-02-19 — — US disclosed
EP-2443123-A2 SMALL MOLECULE INHIBITORS OF SPLEEN TYROSINE KINASE (SYK) Rigel Pharmaceuticals, Inc. (US) 2012-04-25 — — EP disclosed
WO-2010147898-A2 SMALL MOLECULE INHIBITORS OF SPLEEN TYROSINE KINASE (SYK) RIGEL PHARMACEUTICALS, INC. (US) 2010-12-23 — — WO disclosed
US-20100316649-A1 SMALL MOLECULE INHIBITORS OF SPLEEN TYROSINE KINASE (SYK) MIDCAP FINANCIAL TRUST 2010-12-16 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100316649-A1 SMALL MOLECULE INHIBITORS OF SPLEEN TYROSINE KINASE (SYK) SYK, BTK, LCK GAA 502/4885MAPT 4045/4885SMN1; SMN2 2568/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback